Evaluation of the potential interference of camouflage on the treatment of vitiligo: An observer‐blinded self‐controlled study. Issue 1 (26th November 2020)

• Record Type: Journal Article
• Authors: Li, Man; Wang, Fang; Ding, Xiaolan; Xu, Qianxi; Du, Juan
• Is Part Of: Dermatologic therapy. Volume 34:Issue 1(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-11-26
• Subjects: camouflage -- clinical trial -- repigmentation -- safety -- vitiligo; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.14545
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Camouflage improves the quality of life in vitiligo patients. However, whether the use of camouflage interferes the efficacy of the treatment of vitiligo remains controversial. To evaluate the impact and safety of dihydroxyacetone (DHA)‐containing camouflage on the treatment of vitiligo. Thirty patients were enrolled. Comparable vitiliginous patches in each patient were randomly divided into camouflage group or blank group. The therapeutic modalities including topical corticosteroids with or without NB‐UVB phototherapy were applied to both groups of lesions. The outcomes were assessed at baseline and then every 4 weeks for up to 12 weeks, including types of repigmentation patterns, percentage of repigmentation, trans epidermal water loss (TEWL), and adverse events. Twenty‐eight patients completed the study. There were no differences in repigmentation types and percentage of repigmentation at the endpoint of study between two groups. No difference in TEWL was found at the end of the study between the two groups. Temporary skin irritation (itching and tingling) occurred in one patient in camouflage group after phototherapy between 8 and 12 weeks' treatment. DHA‐containing camouflage is a safe make‐up for vitiligo. It has little impact on the efficacy of the treatment of vitiligo or on the function of skin barrier.